FDA

Scott McGovern

· 7 min read

CBD: Hazy Regulations, Huge Rewards Lure Entrepreneurs

The market for CBD is booming in a gray area of the law. Little is clear except there is a lot of money to be made.

Garrett Rudolph

· 12 min read

Federal Regulators Are Blocking the Cannabis Boom but Congress Keeps Them In the Way

The Federal Reserve and FDA want Congress to clarify how to regulate a product that, strictly speaking, is prohibited.

Alex Somjen

· 4 min read

Peter Page

· 8 min read

Here's Why the DEA Re-Scheduling Just One Cannabis-Based Drug Is a Very Big Deal

For decades DEA has insisted marijuana has no legitimate use, even as it made research into medical marijuana nearly impossible. That contradiction is coming to an end.

Evan Eneman and Javier Hasse

· 4 min read

The DEA Actually Didn't Reschedule CBD: Industry Insiders Explain What Epidiolex's Reclassification Really Means

For decades the DEA has insisted nothing derived from cannabis has any legitimate use. Epidiolex is the first exemption that many believe will lead to a new rule.

Javier Hasse

· 5 min read